Whitehawk Therapeutics Completes Strategic Transformation with Successful Closing of Sale of Aadi Subsidiary to Kaken Pharmaceuticals
Whitehawk Therapeutics (Nasdaq: WHWK) has successfully completed its strategic transformation by closing the sale of its Aadi Subsidiary to Kaken Pharmaceuticals for $100 million plus customary adjustments. The transaction, initially announced in December 2024, includes the transfer of Aadi Bioscience name, trademarks, and the FYARRO® business.
The company plans to utilize proceeds from both this divestiture and a recent $100M PIPE financing to advance its antibody drug conjugates (ADCs) portfolio and for general corporate purposes. The combined funding is projected to sustain operations until 2028, supporting key clinical data readouts for three assets.
Whitehawk Therapeutics (Nasdaq: WHWK) ha completato con successo la sua trasformazione strategica chiudendo la vendita della sua controllata Aadi a Kaken Pharmaceuticals per 100 milioni di dollari più le regolazioni consuete. La transazione, annunciata inizialmente a dicembre 2024, include il trasferimento del nome Aadi Bioscience, dei marchi e del business FYARRO®.
L'azienda prevede di utilizzare i proventi sia da questa dismissione che da un recente finanziamento PIPE da 100 milioni di dollari per far progredire il proprio portafoglio di coniugati di farmaci anticorpali (ADC) e per scopi aziendali generali. Si prevede che il finanziamento combinato sostenga le operazioni fino al 2028, supportando letture di dati clinici chiave per tre asset.
Whitehawk Therapeutics (Nasdaq: WHWK) ha completado con éxito su transformación estratégica al cerrar la venta de su subsidiaria Aadi a Kaken Pharmaceuticals por 100 millones de dólares más ajustes habituales. La transacción, anunciada inicialmente en diciembre de 2024, incluye la transferencia del nombre Aadi Bioscience, marcas registradas y el negocio FYARRO®.
La compañía planea utilizar los ingresos tanto de esta desinversión como de un reciente financiamiento PIPE de 100 millones de dólares para avanzar en su cartera de conjugados de fármacos anticuerpos (ADC) y para fines corporativos generales. Se proyecta que la financiación combinada sostenga las operaciones hasta 2028, apoyando la presentación de datos clínicos clave para tres activos.
화이트호크 테라퓨틱스 (Nasdaq: WHWK)는 아디 자회사를 카켄 제약에 1억 달러에 판매하는 계약을 체결하며 전략적 변환을 성공적으로 완료했습니다. 이 거래는 2024년 12월에 처음 발표되었으며, 아디 바이오사이언스의 이름, 상표 및 FYARRO® 사업의 이전을 포함합니다.
회사는 이번 매각과 최근의 1억 달러 PIPE 자금 조달에서 얻은 수익을 항체 약물 접합체(ADC) 포트폴리오를 발전시키고 일반 기업 목적에 사용할 계획입니다. 결합된 자금은 2028년까지 운영을 지속할 것으로 예상되며, 세 가지 자산에 대한 주요 임상 데이터 발표를 지원합니다.
Whitehawk Therapeutics (Nasdaq: WHWK) a réussi à achever sa transformation stratégique en finalisant la vente de sa filiale Aadi à Kaken Pharmaceuticals pour 100 millions de dollars plus des ajustements habituels. La transaction, annoncée initialement en décembre 2024, comprend le transfert du nom Aadi Bioscience, des marques et de l'activité FYARRO®.
L'entreprise prévoit d'utiliser les produits de cette cession ainsi que d'un récent financement PIPE de 100 millions de dollars pour faire avancer son portefeuille de conjugués d'anticorps (ADC) et pour des fins d'entreprise générales. Le financement combiné devrait soutenir les opérations jusqu'en 2028, en soutenant des lectures de données cliniques clés pour trois actifs.
Whitehawk Therapeutics (Nasdaq: WHWK) hat erfolgreich seine strategische Transformation abgeschlossen, indem es den Verkauf seiner Tochtergesellschaft Aadi an Kaken Pharmaceuticals für 100 Millionen Dollar plus übliche Anpassungen abgeschlossen hat. Die Transaktion, die ursprünglich im Dezember 2024 angekündigt wurde, umfasst die Übertragung des Namens Aadi Bioscience, der Marken und des FYARRO®-Geschäfts.
Das Unternehmen plant, die Erlöse aus dieser Veräußering sowie aus einer kürzlichen PIPE-Finanzierung in Höhe von 100 Millionen Dollar zu nutzen, um sein Portfolio an Antikörper-Arzneimittel-Konjugaten (ADCs) voranzutreiben und für allgemeine Unternehmenszwecke. Die kombinierte Finanzierung wird voraussichtlich die Operationen bis 2028 unterstützen und wichtige klinische Datenlesungen für drei Vermögenswerte ermöglichen.
- Received $100 million cash payment from Aadi Subsidiary sale
- Secured additional $100M through PIPE financing
- Extended cash runway through 2028
- Portfolio focused on higher-value ADC therapeutics
- Divestiture of revenue-generating FYARRO® business
Whitehawk expects to use the proceeds from the divestiture, as well as from the recent
About Whitehawk Therapeutics
Whitehawk Therapeutics is a preclinical stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved cancer treatments. Whitehawk's advanced three-asset ADC portfolio is engineered to overcome the limitations of first-generation predecessors to deliver a meaningful impact for patients with difficult-to-treat cancers. These assets are in-licensed from WuXi Biologics under an exclusive development and global commercialization agreement. More information on the Company is available at www.whitehawktx.com and connect with us on LinkedIn.
Forward-Looking Statements
This press release contains certain forward-looking statements regarding the business of Whitehawk Therapeutics that are not a description of historical facts within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on the Company's current beliefs and expectations and may include, but are not limited to, statements relating to: the Company's cash runway extending into 2028; the anticipated timing of the Company's development of its portfolio of ADC assets, including the expected timing regarding the commencement of IND-enabling studies and key clinical data readouts; expectations regarding the beneficial characteristics, safety, efficacy, therapeutic effects and the size of the potential targeted markets with respect to the Company's ADC assets; and the sufficiency of the Company's existing capital resources and the expected timeframe to fund the Company's future operating expenses and capital expenditure requirements. Actual results could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, uncertainties associated with preclinical and clinical development of the ADC portfolio, including potential delays in the commencement, enrollment and completion of clinical trials; and risks related to the Company's estimates regarding future expenses, capital requirements and need for additional financing.
Additional risks and uncertainties that could cause actual outcomes and results to differ materially from those contemplated by the forward-looking statements are included in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2023, including under the caption "Item 1A. Risk Factors," and in Whitehawk's subsequent Quarterly Reports on Form 10-Q, and elsewhere in Whitehawk's reports and other documents that Whitehawk has filed, or will file, with the SEC from time to time and available at www.sec.gov, including the Definitive Proxy Statement filed on January 31, 2025.
All forward-looking statements in this press release are current only as of the date hereof and, except as required by applicable law, Whitehawk undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise. All forward-looking statements are qualified in their entirety by this cautionary statement. This cautionary statement is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
Contact:
IR@whitehawktx.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/whitehawk-therapeutics-completes-strategic-transformation-with-successful-closing-of-sale-of-aadi-subsidiary-to-kaken-pharmaceuticals-302411424.html
SOURCE Whitehawk Therapeutics, Inc.
FAQ
How much did Whitehawk Therapeutics (WHWK) receive for selling Aadi Subsidiary?
What is Whitehawk Therapeutics' (WHWK) cash runway following the March 2025 divestiture?
What assets were included in WHWK's Aadi Subsidiary sale to Kaken Pharmaceuticals?
How will Whitehawk Therapeutics (WHWK) use the proceeds from the March 2025 sale?
